Clinical Trial Update: CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CCT301-38 CAR-T in relapsed or refractory AXl-positive sarcomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• CCT301-38

Snippet

Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Conditions: SAR | Phase 1 | Status: TERMINATED